Introducing our Adjuvant Systems Platform

Our next instalment of the Croda Pharma blog looks at our Adjuvant Systems platform. Keep reading to learn more about how we can support both your current and future needs for vaccine formulations.

Leveraging a history of developing adjuvants since 1939, we pride ourselves in being an innovative and reliable partner for our customers. For this reason, we are a trusted leader with widely recognised brands in the vaccine industry, such as Alhydrogel™, Adju-Phos™ and Quil-A™.

Your trusted adjuvant partner, today and tomorrow

With over 80 years of experience our scientists deliver high quality adjuvants to meet your vaccine formulation needs today. Beyond today we want to meet your formulation needs of the future. Our extensive expertise in immunology and formulation of adjuvant systems means we can partner with you to develop the next generation of vaccines, adapting to your requirements. We use our manufacturing experience to turn novel technologies into commercial GMP products, driven by our purpose to use ‘smart science to improve lives™’

Our adjuvant portfolio

We offer a diverse portfolio of technologies at the highest of production standards. With extensive experience in cGMP manufacturing, we manufacture high quality mineral adjuvants, and saponins. We are constantly working to expand our adjuvant offering to meet market needs and enable the fight against pathogens and enable the development of modern therapeutic vaccines also.

Our adjuvant development pipeline - Cationic Adjuvant Formulation CAF^®

Our adjuvant offering has expanded to offer two CAF adjuvants CAF01 and CAF09b, both showing promise for use in novel vaccines in early life and cancer immunotherapy trials respectively. If you would like to learn more about CAF or any of our other adjuvant offering contact us here.

This pipeline technology, CAF^®, aims to address the weak cell mediated immunity response induced by vaccine antigens. The CAF technology platform is range of new, patented cell mediated immunity inducing cationic liposomal adjuvants.

The CAF range has a number of benefits including:

- Ensure a strong co-localisation between the antigen and adjuvant – key for inducing T-cell immunity

- Prolonged exposure of the antigen to the immune system – improving the memory profiles of the induced immunity

- Initial activation of the immune system is very localised to the injection site – reducing systemic side effects associated with vaccinations e.g. fever and system pain

If you would like to learn more about immunostimulation and where adjuvant technology is headed listen to our webinar with Dr. Dennis Christensen on demand here.

Addressing the challenges of vaccine formulation

12.5 MB

Adjuvant Systems

Your partner for modern vaccine development. Our unique GMP portfolio and outstanding expertise can meet your adjuvant needs. Collaborate with our scientists to create the vaccines of tomorrow.

Take me there

Sustainable Squalene

Our sustainably produced Squalene is based on cutting-edge technology using synthetic biology to obtain squalene from a fermentation process.

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
PHAD™ (MPLA Analogue)

Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells. PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived...

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
CAF01®

Part of our new generation of adjuvants, CAF01 is a liposomal adjuvant formulation that offers excellent long-term stability and drives both humoral and cellular immune responses.

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
CAF09b®

A novel liposomal adjuvant used in cancer immunotherapy trials, CAF09b has the capacity to facilitate the production of CD8+ T-cells.

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
Adju-Phos™

Well-established as a common component in a variety of vaccines, Adju-Phos is an aluminium-based adjuvant that induces strong Th2 immune responses.

Add to favourites Add product to favourites
3D(6-acyl)-PHAD™

Immunostimulatory and highly purified, 3D(6-acyl)-PHAD activates TLR4 to induce proinflammatory cytokines and T-cells. 3D(6-acyl)-PHAD is a synthetically produced structural analogue of monophosphoryl...

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
3D-PHAD™

Highly pure, safe, and chemically stable, 3D-PHAD stimulates the immune system through the activation of TLR4, leading to the production of proinflammatory cytokines, CD4+ and CD8+ T-cells. 3D-PHAD is...

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
Alhydrogel™

One of the most widely used vaccine adjuvants, Alhydrogel is an aluminium-based adjuvant used in clinically-approved vaccines that can elicit effective Th2 immune responses.

Add to favourites Add product to favourites
QS 21

A powerful immunostimulatory saponin that acts as a potent vaccine adjuvant, QS 21 can stimulate both cell-mediated (Th1) and humoral (Th2) immune responses

Speak with an expert about this exclusive product
Add to favourites Add product to favourites
Quil-A™

A versatile immunostimulatory saponin that’s widely used as a potent veterinary adjuvant, Quil-A can work against both intra- and extra-cellular pathogens, stimulating innate and Th-mediated adaptive immune...

Speak with an expert about this exclusive product
Add to favourites Add product to favourites

Published by

Angela Kleiner Marketing Director - Adjuvant Systems & Veterinary Health
Catherine Weaver Graduate Trainee, Medical Genetics BSC, Cancer Molecular Pathology MSc

Published on:

Thursday 2nd February 2023

Croda Pharma: The future of novel excipients

The importance of excipients and their specialised role in formulation development has been recognised in recent years, whether that be for targeting delivery of the drug, aesthetics of the final formulation, or shelf life of the final drug product. Some excipients play a simple role in drug formulations while others require an excipient with different properties to perform their job properly.

View

Promising new results for metastatic prostate cancer vaccine

A new study1 published in Frontiers in Immunology reports promising vaccine results for patients with hormone-sensitive prostate cancer. The researchers demonstrated that a vaccine formulation containing the novel adjuvant CAF®09b and a Bcl-XL-peptide was able to elicit potent CD4+ and CD8+ T-cell responses. The team believes these findings can have an influential impact on the future of prostate cancer treatment. Dennis Christensen, Croda's Head of Global R&D, says that the "data shows that CAF®09b is a promising adjuvant for antigen-specific cancer immunotherapies".

Lipid Leaders: Dennis Christensen

In this Lipid Leaders interview, we get insight from Croda Pharma's own Global Head of R&D - Adjuvant Systems, Dennis Christensen, PhD. Keep reading to learn more about adjuvants and the role they play in vaccines, as well as where the technology may be heading.

Please provide an enquiry type

Country